1054315-41-1Relevant articles and documents
Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3- (6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl) pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kin
Velaparthi, Upender,Wittman, Mark,Liu, Peiying,Carboni, Joan M.,Lee, Francis Y.,Attar, Ricardo,Balimane, Praveen,Clarke, Wendy,Sinz, Michael W.,Hurlburt, Warren,Patel, Karishma,Discenza, Lorell,Kim, Sean,Gottardis, Marco,Greer, Ann,Li, Aixin,Saulnier, Mark,Yang, Zheng,Zimmermann, Kurt,Trainor, George,Vyas, Dolatrai
, p. 5897 - 5900 (2008)
We previously reported that 1 (BMS-536924), a benzimidazole inhibitor of the insulin-like growth factor-1 receptor, had demonstrated in vivo antitumor activity. This lead compound was found to have potent CYP3A4 inhibition, CYP3A4 induction mediated by PX